The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
Abstract
Key Points: Treatment with vemurafenib induced a dramatic response in 3 patients with histiocytosis harboring BRAF V600E mutations. Tumor response was observed in both Erdheim-Chester disease and Langerhans cell histiocytosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
Langerhans cell histiocytosis: Diagnosis, natural history, management, and outcome
Howarth, D. M., Gilchrist, G. S., Mullan, B. P., Wiseman, G. A., Edmonson, J. H., & Schomberg, P. J. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990515)85:10<2278::aid-cncr25>3.0.co;2-u · Cited by 725
Haroche, J., Charlotte, F., Arnaud, L., von Deimling, A., Hélias-Rodzewicz, Z., Hervier, B., Cohen-Aubart, F., Launay, D., Lesot, A., Mokhtari, K., et al. (2012) · Blood · doi:10.1182/blood-2012-05-430140 · Cited by 696
Self-citationCapper, D., Preusser, M., Habel, A., Sahm, F., Ackermann, U., Schindler, G., Pusch, S., Mechtersheimer, G., Zentgraf, H., & von Deimling, A. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0841-z · Cited by 472
Arnaud, L., Hervier, B., Néel, A., Hamidou, M. A., Kahn, J.-E., Wechsler, B., Pérez-Pastor, G., Blomberg, B., Fuzibet, J.-G., Dubourguet, F., et al. (2011) · Blood · doi:10.1182/blood-2010-06-294108 · Cited by 383
Self-citationBRAF Inhibition in Refractory Hairy-Cell Leukemia
Dietrich, S., Glimm, H., Andrulis, M., von Kalle, C., Ho, A. D., & Zenz, T. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1202124 · Cited by 255
Sahm, F., Capper, D., Preusser, M., Meyer, J., Stenzinger, A., Lasitschka, F., Berghoff, A.-S., Habel, A., Schneider, M., Kulozik, A., et al. (2012) · Blood · doi:10.1182/blood-2012-06-429597 · Cited by 221
Haroche, J., Arnaud, L., & Amoura, Z. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834d861d · Cited by 204
Self-citationSatoh, T., Smith, A., Sarde, A., Lu, H., Mian, S., Trouillet, C., Mufti, G. J., Emile, J., Fraternali, F., Donadieu, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033891 · Cited by 156
Self-citation
Cited by
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Diamond, E. L., Dagna, L., Hyman, D. M., Cavalli, G., Janku, F., Estrada-Veras, J., Ferrarini, M., Abdel-Wahab, O., Heaney, M. L., Scheel, P. J., et al. (2014) · Blood · doi:10.1182/blood-2014-03-561381 · Cited by 586
Self-citationRodriguez-Galindo, C., & Allen, C. E. (2020) · Blood · doi:10.1182/blood.2019000934 · Cited by 361
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease
Garces, S., Medeiros, L. J., Patel, K. P., Li, S., Pina-Oviedo, S., Li, J., Garces, J. C., Khoury, J. D., & Yin, C. C. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.55 · Cited by 299
Metadata
- Authors
- Haroche, J., Cohen-Aubart, F., Emile, J.-F., Arnaud, L., Maksud, P., Charlotte, F., Cluzel, P., Drier, A., Hervier, B., Benameur, N., Besnard, S., Donadieu, J., & Amoura, Z.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-02-28
- Volume
- 121
- Issue
- 9
- Pages
- 1495-1500
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2006268804
- Cited by
- 537
- References
- 12
- FWCI
- 31.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. https://app.cochat.ai/papers/10.1182/blood-2012-07-446286
- The paper
- Haroche, J., Cohen-Aubart, F., Emile, J.-F., Arnaud, L., Maksud, P., Charlotte, F., Cluzel, P., Drier, A., Hervier, B., Benameur, N., Besnard, S., Donadieu, J., & Amoura, Z. (2013). Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. https://doi.org/10.1182/blood-2012-07-446286
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
